Amoy Diagnostics Co Ltd
SZSE:300685

Watchlist Manager
Amoy Diagnostics Co Ltd Logo
Amoy Diagnostics Co Ltd
SZSE:300685
Watchlist
Price: 20.55 CNY -1.77%
Market Cap: 8.1B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Amoy Diagnostics Co Ltd stock under the Base Case scenario is 36.58 CNY. Compared to the current market price of 20.55 CNY, Amoy Diagnostics Co Ltd is Undervalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
36.58 CNY
Undervaluation 44%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.9
P/S
P/S
Price to Sales
6.9
vs History
88
vs Industry
49
Median 3Y
10.3
Median 5Y
11.5
Industry
6.5
Forward
6.4
More Details
26
P/E
P/E
Price to Earnings
26
vs History
93
vs Industry
6
Median 3Y
33.3
Median 5Y
41.3
Industry
22
Forward
26.3
More Details
25.3
P/OCF
P/OCF
Price to OCF
25.3
vs History
88
vs Industry
6
Median 3Y
36.5
Median 5Y
45.3
Industry
18.4
More Details
28.1
P/FCFE
P/FCFE
Price to FCFE
28.1
vs History
87
vs Industry
7
Median 3Y
44.5
Median 5Y
60.1
Industry
23.4
More Details
4.5
P/B
P/B
Price to Book Value
4.5
vs History
88
vs Industry
19
Median 3Y
6.1
Median 5Y
7.1
Industry
2.2
More Details
6
EV/S
EV/S
Enterprise Value to Sales
6
vs History
88
vs Industry
43
Median 3Y
9.4
Median 5Y
10.7
Industry
7.1
Forward
5.6
More Details
7.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.1
vs History
88
vs Industry
45
Median 3Y
11.4
Median 5Y
12.8
Industry
8.7
More Details
21
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
21
vs History
92
vs Industry
6
Median 3Y
37.6
Median 5Y
42.8
Industry
3.3
Forward
18.7
More Details
21
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
21
vs History
92
vs Industry
6
Median 3Y
37.6
Median 5Y
42.8
Industry
3.1
Forward
21.3
More Details
22
EV/OCF
EV/OCF
Enterprise Value to OCF
22
vs History
88
vs Industry
7
Median 3Y
33.4
Median 5Y
43.3
Industry
4
More Details
24.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
24.6
vs History
88
vs Industry
5
Median 3Y
40.3
Median 5Y
65.8
Industry
2.6
More Details
7.7
EV/IC
EV/IC
Enterprise Value to IC
7.7
vs History
85
vs Industry
21
Median 3Y
9.2
Median 5Y
11.3
Industry
4.3
More Details

Multiples Across Competitors

Competitors Multiples
Amoy Diagnostics Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Amoy Diagnostics Co Ltd
SZSE:300685
8.2B CNY 6.9 26 21 21
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 837 576.7 -165 577.8 -201 064.3 -198 769.9
US
Abbvie Inc
NYSE:ABBV
303.1B USD 5.4 71.5 14.4 21.7
US
Amgen Inc
NASDAQ:AMGN
151.7B USD 4.5 37.1 15.3 27
US
Gilead Sciences Inc
NASDAQ:GILD
130.7B USD 4.5 272.3 10.7 13.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.6B USD 11.3 -232.7 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 022.2 -516 -561.9 -546.9
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.2 16.8 21
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.2B USD 4.2 13.6 8.2 9.1
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58
NL
argenx SE
XBRU:ARGX
31.7B EUR 16.5 43.3 319.7 -2 355.4
P/S Multiple
Revenue Growth P/S to Growth
CN
Amoy Diagnostics Co Ltd
SZSE:300685
Average P/S: 3 167 243.3
6.9
21%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 837 576.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.4
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
2 022.2
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
7%
0.6
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
NL
argenx SE
XBRU:ARGX
16.5
37%
0.4
P/E Multiple
Earnings Growth PEG
CN
Amoy Diagnostics Co Ltd
SZSE:300685
Average P/E: 70.1
26
22%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 577.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
71.5
87%
0.8
US
Amgen Inc
NASDAQ:AMGN
37.1
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
272.3
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -232.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516 N/A N/A
AU
CSL Ltd
ASX:CSL
27.2
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
12%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
NL
argenx SE
XBRU:ARGX
43.3
26%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Amoy Diagnostics Co Ltd
SZSE:300685
Average EV/EBITDA: 53.9
21
22%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 064.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
14%
1
US
Amgen Inc
NASDAQ:AMGN
15.3
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.9 N/A N/A
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.2
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
NL
argenx SE
XBRU:ARGX
319.7
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Amoy Diagnostics Co Ltd
SZSE:300685
Average EV/EBIT: 20
21
19%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 769.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.7
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
27
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.1
17%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 355.4 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.